Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196601 | 0.77 | GPR3 (0.64) | GPR3ALDH1A1CYP1A2HSD17B10HPGD | |
| Ammonia Solution, Strong SCHEMBL2184448 | 0.76 | GPR3 (0.61) | GPR3ALDH1A1CYP1A2HSD17B10HPGD | |
| SCHEMBL19054771 | 0.75 | ADORA2A (0.68) | GPR3ALDH1A1CYP1A2HSD17B10HPGD | |
| SCHEMBL8531235 | 0.75 | ADORA2A (0.68) | ALDH1A1CYP1A2NUDT1NPC1MEN1 | |
| SCHEMBL85621 | 0.75 | GPR3 (1.00) | GPR3ALDH1A1CYP1A2HSD17B10HPGD | |
| SCHEMBL377227 | 0.74 | HSD17B10 (1.00) | GPR3ALDH1A1CYP1A2HSD17B10HPGD | |
| SCHEMBL10701764 | 0.74 | DCPS (0.63) | ALDH1A1CYP1A2HSD17B10HPGDNUDT1 | |
| SCHEMBL11581679 | 0.74 | GPR3 (0.59) | GPR3ALDH1A1CYP1A2HSD17B10HPGD | |
| SCHEMBL18574483 | 0.74 | GPR3 (0.59) | GPR3ALDH1A1CYP1A2HSD17B10HPGD | |
| SCHEMBL4681829 | 0.74 | GPR3 (0.59) | GPR3ALDH1A1CYP1A2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| CN-1882345-A | 2, 6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as RAF kinase inhibitors for the treatment of cancer | CHIRON CORP (US) | 2006-12-20 | — | — | CN | disclosed |
| EP-0337308-B1 | 2-Pyridylmethylthio derivatives and antiulcer agents | NISSHIN FLOUR MILLING CO (JP) | 1994-11-30 | — | — | EP | disclosed |
| US-4925843-A | SUBSTITUTED ON QUINAZOLINE, PHTHALAZINE OR PYRIDO(2,3-D)PYRIMIDINE MOIETIES | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| EP-0337308-A2 | 2-Pyridylmethylthio derivatives and antiulcer agents | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | GPR3 2438/4885ALDH1A1 399/4885CYP1A2 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.